{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:04:43Z","timestamp":1791194683027,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/inf.0000000000000491","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T03:43:04Z","timestamp":1406346184000},"page":"e23-e31","source":"Crossref","is-referenced-by-count":24,"title":["Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy"],"prefix":"10.1097","volume":"34","author":[{"given":"Mutsawashe","family":"Bwakura-Dangarembizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Musiime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Szubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Prendergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvenyika A.","family":"Gomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J.","family":"Thomason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuthbert","family":"Musarurwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mugyenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Nahirya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeodata","family":"Kekitiinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusum","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210202","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0b013e31824330cb","article-title":"European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.","volume":"59","author":"Alam","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R2-10-20210202","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006454-200205000-00011","article-title":"Lipodystrophy syndrome in human immunodeficiency virus-infected children.","volume":"21","author":"Amaya","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R3-10-20210202","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/QAD.0b013e32832b7e69","article-title":"Longitudinal changes in regional fat content in HIV-infected children and adolescents.","volume":"23","author":"Arpadi","year":"2009","journal-title":"AIDS"},{"key":"R4-10-20210202","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/135965350701200811","article-title":"Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.","volume":"12","author":"Aurpibul","year":"2007","journal-title":"Antivir Ther"},{"key":"R5-10-20210202","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.anpedi.2011.12.005","article-title":"Characteristics of human immunodeficiency virus-1 infected children receiving highly active antiretroviral therapy: a cross-sectional study.","volume":"76","author":"Badillo","year":"2012","journal-title":"An Pediatr (Barc)"},{"key":"R6-10-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.qai.0000178930.93033.f2","article-title":"Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.","volume":"40","author":"Beregszaszi","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-10-20210202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00431-006-0193-1","article-title":"Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.","volume":"166","author":"Ene","year":"2007","journal-title":"Eur J Pediatr"},{"key":"R9-10-20210202","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2431-12-183","article-title":"High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.","volume":"12","author":"Innes","year":"2012","journal-title":"BMC Pediatr"},{"key":"R10-10-20210202","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/00002030-200009290-00008","article-title":"Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.","volume":"14","author":"Jaquet","year":"2000","journal-title":"AIDS"},{"key":"R11-10-20210202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/157016209788347912","article-title":"The prognosis of pediatric AIDS in serbia.","volume":"7","author":"Jevtovic","year":"2009","journal-title":"Curr HIV Res"},{"key":"R12-10-20210202","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3851\/IMP1897","article-title":"PREDICT study group. High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression.","volume":"16","author":"Kanjanavanit","year":"2011","journal-title":"Antivir Ther"},{"key":"R13-10-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/INF.0b013e3182755a34","article-title":"Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.","volume":"32","author":"Kinabo","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R14-10-20210202","doi-asserted-by":"crossref","first-page":"17427","DOI":"10.7448\/IAS.15.2.17427","article-title":"Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.","volume":"15","author":"Piloya","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"R15-10-20210202","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1590\/S1413-86702008000400018","article-title":"Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus.","volume":"12","author":"Alves","year":"2008","journal-title":"Braz J Infect Dis"},{"key":"R16-10-20210202","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00126334-200105010-00005","article-title":"Lipodystrophy in HIV-infected children is associated with high viral load and low CD4 -lymphocyte count and CD4 -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.","volume":"27","author":"Arpadi","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-10-20210202","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.qai.0000218344.88304.db","article-title":"Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis.","volume":"41","author":"Carter","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-10-20210202","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/INF.0b013e3181db741b","article-title":"Spanish Group of Pediatric HIV Infection. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavirritonavir-based therapy.","volume":"29","author":"Resino","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R20-10-20210202","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/archdischild-2012-302633","article-title":"Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.","volume":"98","author":"Arpadi","year":"2013","journal-title":"Arch Dis Child"},{"key":"R21-10-20210202","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3851\/IMP2695","article-title":"Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3-trial.","volume":"19","author":"Musiime","year":"2014","journal-title":"Antivir Ther"},{"key":"R26-10-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/INF.0b013e31827f4eff","article-title":"Pediatric HIVAIDS Cohort Study. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.","volume":"32","author":"Purswani","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R28-10-20210202","doi-asserted-by":"crossref","first-page":"e63623","DOI":"10.1371\/journal.pone.0063623","article-title":"Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction.","volume":"8","author":"de Waal","year":"2013","journal-title":"PLoS One"},{"key":"R29-10-20210202","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.","volume":"27","author":"Shubber","year":"2013","journal-title":"AIDS"},{"key":"R30-10-20210202","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/QAI.0b013e3182423668","article-title":"Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda.","volume":"59","author":"Tukei","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R36-10-20210202","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/sim.4780132207","article-title":"Age-related reference ranges: significance tests for models and confidence intervals for centiles.","volume":"13","author":"Wade","year":"1994","journal-title":"Stat Med"},{"key":"R39-10-20210202","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/INF.0b013e31823f0e11","article-title":"Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.","volume":"31","author":"Aurpibul","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R40-10-20210202","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/QAD.0b013e3280e087e7","article-title":"Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudineabacavir maintains virological superiority over zidovudinelamivudine and zidovudineabacavir beyond 5 years in children.","volume":"21","author":"Green","year":"2007","journal-title":"AIDS"},{"key":"R42-10-20210202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/INF.0000000000000222","article-title":"Virologic response in children treated with abacavir compared with stavudine-based antiretroviral treatment - a South African multi-cohort analysis.","volume":"33","author":"Technau","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R44-10-20210202","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cid\/cit120","article-title":"First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.","volume":"56","author":"Liu","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R45-10-20210202","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1590\/S1807-59322008000400003","article-title":"High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease.","volume":"63","author":"da Luz","year":"2008","journal-title":"Clinics (Sao Paulo)"},{"key":"R46-10-20210202","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.","volume":"1","author":"van Leth","year":"2004","journal-title":"PLoS Med"},{"key":"R47-10-20210202","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/518973","article-title":"SIROCCO study team. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.","volume":"45","author":"Parienti","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R49-10-20210202","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1001\/jama.2013.3710","article-title":"Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.","volume":"309","author":"Lowenthal","year":"2013","journal-title":"JAMA"},{"key":"R51-10-20210202","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/QAI.0b013e31821d33be","article-title":"Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV.","volume":"57","author":"Rhoads","year":"2011","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201502000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:23:49Z","timestamp":1786047829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201502000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000491","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}